口服贝沙罗汀治疗后循环中 Sézary 细胞凋亡缺失。
Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
作者信息
Brennand S, Sutton V R, Biagi J, Trapani J A, Westerman D, McCormack C J, Seymour J F, Kennedy G, Prince H M
机构信息
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Australia.
出版信息
Br J Dermatol. 2005 Jun;152(6):1199-205. doi: 10.1111/j.1365-2133.2005.06539.x.
BACKGROUND
Apoptosis of malignant cells has been suggested as an important mechanism of the action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL).
OBJECTIVES
Our purpose was to examine the in vivo and in vitro responses of patients with Sézary syndrome treated with oral bexarotene and assess them for apoptosis of the Sézary cells.
METHODS
Six patients with CTCL with circulating Sézary cells, participating in a clinical trial of oral bexarotene (300 mg m(-2) daily) were included in the study. Peripheral blood from the patients was analysed for in vivo and in vitro apoptosis.
RESULTS
None of the six patients demonstrated in vivo apoptosis. In vitro apoptosis of Sézary cells was demonstrated in one patient following exogenous bexarotene.
CONCLUSIONS
Apoptosis is not detectable in the circulation of patients with Sézary syndrome treated with bexarotene.
背景
恶性细胞凋亡被认为是贝沙罗汀治疗皮肤T细胞淋巴瘤（CTCL）的重要作用机制。
目的
我们的目的是研究口服贝沙罗汀治疗的Sezary综合征患者的体内和体外反应，并评估Sezary细胞的凋亡情况。
方法
6例伴有循环Sezary细胞的CTCL患者参与了口服贝沙罗汀（每日300mg/m²）的临床试验，纳入本研究。分析患者外周血的体内和体外凋亡情况。
结果
6例患者均未表现出体内凋亡。1例患者在外源性给予贝沙罗汀后出现了Sezary细胞的体外凋亡。
结论
在接受贝沙罗汀治疗的Sezary综合征患者的循环中未检测到凋亡。
Zotero 插件